Determining the effects of RAD51C ovarian cancer variants
Determining the effects of RAD51C ovarian cancer variants
批准号:
10461516
负责人:
Hayley Rein
金额:
$4.68万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-01 至 2024-09-30
关键词:
ATP phosphohydrolaseAffectBiological AssayCRISPR/Cas technologyCellsCisplatinComet AssayComplementComplexDNADNA DamageDNA Double Strand BreakDNA RepairDataDefectDouble Strand Break RepairFiberFilamentFluorescence MicroscopyGene DuplicationHereditary Breast CarcinomaHumanHybridsIndividualInitiator CodonKineticsKnock-outLeadMalignant NeoplasmsMalignant neoplasm of ovaryMediatingMicroscopyMolecularMutateMutationNuclear ExtractOvarianPathway interactionsPatientsPersonsPoint MutationProcessProductionProteasome InhibitorProtein IsoformsProteinsRAD51C geneRad51 recombinaseRegulationResectedRiskSerousSiteTimeTranslationsVariantWestern BlottingWorkYeastscancer cellcancer preventioncancer subtypesfluorescence microscopegamma irradiationgenetic varianthomologous recombinationirradiationmutantparalogous genepreventprotein degradationrepairedribosome profilingsingle moleculetreatment planningtreatment responsevariant of unknown significance
中文摘要
项目总结/摘要
大约50%的高级别浆液性卵巢癌(HGSOC)缺乏同源重组
(人力资源)。HR是一种高保真DNA双链断裂修复途径,其使用同源模板来修复DNA双链断裂。
精确的DNA修复这一过程的中心蛋白质RAD 51受到严格调控。一组蛋白质
调节RAD 51的是RAD 51旁系同源物,包括RAD 51 C和RAD 51 D。RAD51C
和RAD 51 D在8%的HR缺陷型家族性卵巢癌中突变。尽管RAD 51旁系同源物
20多年前发现了它们在HR中的确切功能,以及这些蛋白质的突变如何促成HGSOC
仍然未知。我们已经鉴定了两种可能的RAD 51 C蛋白同种型,它们可以单独地执行功能。
RAD 51 C变体中的功能,其将阻止任一同种型的蛋白质产生。
32个独立的个体因此,我们提出了这些异构体和突变的功能分析,破坏,
他们的生产。此外,我们还鉴定了RAD 51 C中的突变,这些突变破坏了RAD 51 C与
RAD51D。我们的初步数据已经确定,RAD 51 C和
RAD 51 D是人类细胞中HR效率的良好指标。然而,这种RAD 51 C-RAD 51 D相互作用
对HR的贡献是未知的。我们将研究这些变体对RAD 51蛋白调节的影响。
和使用单分子荧光显微镜(C-trap)的细丝动力学。通过描述
在这些RAD 51 C变体中,我们将揭示WT-RAD 51 C的功能以及功能失调的RAD 51 C是如何产生的。
变异导致HGSOC中的HR缺陷。
英文摘要
Project Summary/ Abstract
Approximately 50% of high grade serous ovarian cancers (HGSOC) are deficient in homologous recombination
(HR). HR is a high-fidelity DNA double-strand break repair pathway which uses a homologous template for
accurate DNA repair. The central protein of this process, RAD51, is tightly regulated. One group of proteins
that work to regulate RAD51 are the RAD51 paralogs, including RAD51C and RAD51D. Collectively, RAD51C
and RAD51D are mutated in 8% of HR deficient familial ovarian cancers. Although the RAD51 paralogs were
discovered 20+ years ago their exact function in HR, and how mutation in these proteins contribute to HGSOC
is still unknown. We have identified two possible RAD51C protein isoforms which may perform separate
function in HR. RAD51C variants that would prevent protein production of either isoform have been identified in
32 separate individuals. Thus, we propose a functional analysis of these isoforms and mutations which disrupt
their production. In addition, we have also identified mutations in RAD51C which disrupt its interaction with
RAD51D. Our preliminary data has determined that the yeast-three-hybrid interaction between RAD51C and
RAD51D is a good indicator of HR efficiency in human cells. Yet, how this RAD51C-RAD51D interaction
contributes to HR is still unknown. We will examine the effects of these variants on RAD51 protein regulation
and filament dynamics using single-molecule fluorescence microscopy (C-trap). By characterizing the activity
of these RAD51C variants we will uncover both the function of WT-RAD51C and how dysfunctional RAD51C
variants contribute to HR deficiency in HGSOC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Determining the effects of RAD51C ovarian cancer variants
-
批准号:10589045
-
项目类别:
-
资助金额:$3.56万
-
财政年份:2022
-
负责人:Hayley Rein
-
依托单位:
海外基金